Register By January 29 & Save $190

March 2-4, 2021 | Digital Event

www.ckd3-summit.com

3rd Annual

Digital

CKD3

Chronic Kidney Disease Drug Development

Advance More Innovative, Targeted & Clinically Successful Therapeutics for Chronic Kidney Diseases

Your 43 Expert Speakers Include:

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Uptal Patel
Executive Director of Clinical Research & Head of Nephrology
Gilead

Maria Gomez
Professor of Physiology
Head, Diabetic Complications Unit
Director
Lund University Diabetes Centre (LUDC)

Jyothis George
Vice President, Clinical, Medical & Regulatory
Novo Nordisk

Matthias Kretzler
Professor of Medicine
Nephrology/ Internal Medicine & Bioinformatics
University of Michigan

Aliza Thompson
Clinical Team Leader, Division of Cardiovascular & Renal Products
FDA

Partners:

BPM BIO PREVENTIVE MEDICINE · NIPOKA · NORDIC BIOSCIENCE · Discovery BioMed · evotec · Frenova Renal Research · gubra

+1 617 455 4188 · info@hansonwade.com · ckd3-summit.com

hansonwade

Welcome to the 3rd Annual Gathering of Chronic Kidney Disease Drug Developers: CKD3

Overcome the translational challenges limiting the development of the next generation of CKD therapeutics.

For the 3rd year, the **Chronic Kidney Disease Drug Development Summit (CKD3)** is putting the hottest topics in CKD drug development under the spotlight.

Across 3 days of content, the world-class faculty will address questions including: what is the drug development opportunity beyond current standards of care including SGLT-2 and GLP-1, how is pharma harnessing the power of AI and what kidney organoids are providing innovation to target identification? CKD3 is the **definitive, intimately focused forum promoting cross stakeholder discussion and networking** to accelerate the next line of CKD drugs.

Built with insight from **30+ kidney heavy weights** including **Reata Pharmaceuticals**, **AstraZeneca**, **Goldfinch Bio** and **Boehringer Ingelheim**, the 3rd CKD3 Summit will comprehensively analyze the challenges in CKD drug development **from genetics to costing,** providing the thought-leading synthesis of all the information you need to accelerate meaningful therapeutics to renal disease patients.

Hear what previous attendees have to say

"This was the best pragmatic development conference for fibrosis that I have been too"

Biogen

"Thought this disease specific conference was informative, by planning a concentrated topic it gave an opportunity to look through a tighter lens"

Genentech
A Member of the Roche Group

What's New for 2021?

- **80+** Attendees
- **50** Organizations
- **38** Speakers
- **5** Panel Discussions
- **1** Poster Session

Your Top 5 Takeaways From Key Stakeholders:

In-Depth Understanding of the Promise, Practicalities & Progress in Precision Medicine from Concept to Clinical Trials

Analyze the precision medicine opportunity in renal disease with the latest insights correlating genetic markers to outcomes in specific populations with **University of Michigan**, **Vertex Pharmaceuticals**, **Goldfinch Bio** and **Chinook Therapeutics**

Strategies to Build a Business Case for Intervention in a World of SGLT-2 Inhibition

Dissect the mechanisms of action driving the beneficial effects of SGLT-2 inhibition in renal disease and strategize the opportunity for additional drug development to deliver greater benefit to patients with **AstraZeneca**, **Boehringer Ingelheim** and **Janssen Pharmaceuticals**

Critically Assess the Predictability of Kidney Organoids for Disease Modeling & Drug Discovery

Evaluate novel *ex vivo* modalities to better predict efficacy of your candidate, more confidently confirm rationale in human context and understand mechanism-based patient stratification with the **Universities of Washington** and **Michigan**

Dramatically Change the Patient Experience in & After Clinical Trials

Hear the patients' perspectives to inform trial design, prioritize outcomes important to the patient and navigate enrollment of minority population for more successful recruitment with **NephCure**, **The Patient Voice** and **Otsuka Pharmaceuticals**

Navigate Trial Endpoints in a Therapeutic World Without Regulatory Precedent

Learn from late stage clinical trials assessing composite endpoints alongside eGFR slope, biomarkers to support drug development and achieving regulating approval in orphan indications for a greater public health impact with **Chinook Therapeutics**, **AstraZeneca** and **inRegen**

Your 43 Expert Speakers

Aliza Thompson
Clinical Team Leader, Division of Cardiovascular & Renal Products
FDA

Andrew King
Head of Renal Discovery & Translational Medicine
Chinook Therapeutics

Anjali Pandey
Senior Vice President of Nonclinical R&D & Chemistry
twoXAR Pharmaceuticals

Beno Freedman
Assistant Professor, Nephrology
University of Washington

Borut Cizman
Senior Director & Lead Nephrologist, ASCEND Program, Specialty Pharma, R&D
GSK

Dorothee Oberdhan
Associate Director, Health Outcomes
Otsuka Pharmaceuticals

Frank Czerwiec
Chief Medical Officer
Goldfinch Bio

Federica Genovese
Director of Renal & Cardiovascular Research
Nordic Bioscience

Harry Alcorn
Chief Medical Officer
Diamedica

Hitesh Soni
Renal Fibrosis Gene Therapy Lead
Renascent Biosciences

Jeff Hafkin
Senior Director
Otsuka Pharmaceuticals

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Jerome Rossert
Vice President, Head of Clinical Renal
AstraZeneca

Jonathan Himmelfarb
Director of the Kidney Research Institute & Professor of Medicine
University of Washington

Joseph Stavas
Senior Vice President, Clinical Development
inRegen

Josh Tarnoff
Chief Executive Officer
NephCure Kidney International

Julie Williams
Director/Science Lead Bioscience Renal
AstraZeneca

Jyothis George
Vice President, Clinical, Medical & Regulatory
Novo Nordisk

Kevin Fowler
President
The Voice of the Patient

Liron Walsh
Vice President of Translational & Clinical Nephrology
Goldfinch Bio

Maria Chiara Magnone
Vice President Kidney Diseases & Boston Site Head
Janssen

Your 43 Expert Speakers

Maria Gomez
Professor of Physiology
Head, Diabetic Complications Unit
Director
Lund University Diabetes Centre (LUDC)

Matt Breyer
Distinguished Scientist
Janssen

Matt Devalaraja
Chief Scientific Officer, Head of Research & Development
Corvidia Therapeutics

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics
University of Michigan

Nick LaBella
Chief Scientific Officer
ZyVersa Therapeutics

Nicole Endlich
Chief Executive Officer, **NIPOKA**; Professor
University Medicine Greifswald

Pernille Hansen
Senior Director & Head of Bioscience
AstraZeneca

Rafael Kramann
Professor of Medicine, Chairman Institute of Experimental Medicine & Systems Biology
RWTH Aachen

Radko Komers
Senior Medical Director, Nephrology
Travere Therapeutics

Ravi Kumar
Senior Vice President & Chief Scientific Officer
Acceleron Pharma

Richard Nkulikiyinka
VP, Head of Therapeutic Area Cardiology & Nephrology
Bayer Pharmaceuticals

Robert Edwards
Clinical Project Scientist
Janssen

Ron Perrone
Scientific Director, Clinical & Translational Research Center; Professor
Tufts University School of Medicine

Seemi Khan
Senior Vice President, Chief Medical Officer
Reata Pharmaceuticals

Scott MacDonnell
Associate Director, Cardiovascular & Fibrosis Research
Regeneron Pharmaceuticals

Shira Perl
Global Clinical Program Lead
AstraZeneca

Tzu-Ling (Karen) Tseng
Chief Executive Officer
Bio Preventive Medicine Corp

Sibylle Hauske
Senior Medical Director & Global Clinical Development Lead - Empagliflozin in CKD
Boehringer Ingelheim

Uptal Patel
Executive Director of Clinical Research & Head of Nephrology
Gilead

Vishal Vaidya
Translational Omics Group Head
Pfizer

Wenjun Ju
Associate Research Scientist of Internal Medicine
University of Michigan

Yshai Yavin
Director, Cardiovascular & Metabolism Development
Janssen

> "Hanson Wade did a phenomenal job! Definitely the most productive conference so far this year regarding the number of leads and quality of networking opportunities by a lot."
>
> **IPF Summit, Digital Attendee**

Pre-Conference Discussion

Tuesday March 2

Eastern Standard Time | Pacific Standard Time

Scientific Theory to Drug Development Workshop
Sharing & Discussing Updates From Early & Late Stage Development

Rafael Kramann
Professor of Medicine, Chairman Institute of Experimental Medicine & Systems Biology
RWTH Aachen

10.30 | 7.30

Mapping Human Chronic Kidney Disease on Single Cell Level

- Discussing scRNA-seq to map human CKD and none CKD
- Identifying cells that drive kidney fibrosis in human and mouse
- Harnessing scRNA-seq to identify potential therapeutic targets

Nick LaBella
Chief Scientific Officer
ZyVersa Therapeutics

11.00 | 8.00

Renal Lipids as a Potential Therapeutic Target for Kidney Disease

- Describing evidence of lipid accumulation in podocytes
- Association of lipid accumulation with decreased cholesterol efflux
- Positioning cholesterol efflux as a therapeutic approach the management of renal disease

Hitesh Soni
Renal Fibrosis Gene Therapy Lead
Renascent Biosciences

11.30 | 8.30

Role of Vascular Smooth Muscle Cell (SMC) TRPV4 Channel in Ischemia-Reperfusion-Induced Renal Insufficiency in Neonatal Pigs

- Discussing different animal studies using ischemia-reperfusion (IR) and nephrotoxic injuries to investigate pathophysiologic events involved in AKI to CKD progression
- Sharing data showing bilateral renal IR in pigs increased TRPV4 channel protein expression in renal microvessels; and pharmacological inhibition of TRPV4 attenuated renal insufficiency caused by bilateral renal IR
- Evaluating TRPV4 as a potential therapeutic target for amplified renovascular resistance in the early phase of neonatal AKI and its involvement in AKI to CKD progression

12.00 | 9.00 **Lunch Break & Networking**

Matt Devalaraja
Chief Scientific Officer, Head of Research & Development
Corvidia Therapeutics

12.30 | 9.30

Inflammation at the Heart of Chronic Kidney Disease Patients: Anti-Interleukin Therapy?

- Inflammation drives not only the progression of chronic kidney disease but also increases the cardiovascular morbidity and mortality in these patients
- Understanding interleukin-6 as the likely central mediator of increased cardiovascular risk and targeting therapy to neutralize IL-6 as an effective strategy to decrease CVD in these CKD patients

Harry Alcorn
Chief Medical Officer
Diamedica

1.00 | 10.00

CKD DM199 Research Update

- An overview of DM199 Phase 1b Results in diabetic patients with CKD (Stage III / IV)
- Sharing DM199 Phase II late breaking data in African American with CKD, hypertension and non diabetic IgA nephropathy patients

Ron Perrone
Scientific Director, Clinical & Translational Research Center; Professor
Tufts University School of Medicine

1.30 | 10.30

Research Update in Polycystic Kidney Disease

- Discussing the assessment of the risk of rapid progression
- Total kidney volume as a prognostic biomarker
- Ongoing clinical trials in ADPKD

2.00 | 11.00 **Pre-conference Discussion Ends**

Conference Day One
Wednesday March 3

Eastern Standard Time | Pacific Standard Time

Plenary Moderator: Jerome Rossert, Vice President, Head of Clinical Renal, **AstraZeneca**

Kevin Fowler
President
The Voice of the Patient

8.15 | 5.15

The Value Proposition of Early Identification & Intervention of Kidney Disease

- Understand the value proposition of early detection and intervention of kidney diseases
- Setting the tone: why now is the time to invest in kidney diseases treatments
- Discuss the barriers to innovation

What's Next?
Opportunities for Additional Drug Development & Addressing Multiple Areas with Treatment

Jyothis George
Vice President, Clinical, Medical & Regulatory
Novo Nordisk

8.30 | 5.30

Interplay Between Diabetes, Heart Disease & CKD: What Can we Learn from Novel Drug Development?

- Session details to follow

Richard Nkulikiyinka
VP, Head of Therapeutic Area Cardiology & Nephrology
Bayer Pharmaceuticals

9.00 | 6.00

Remaining Unmet Medical Need in Chronic Kidney Disease: Challenges & Opportunities for Additional Drug Development

- Unmet clinical needs in CKD following recent successes of SGLT2 inhibitors and finerenone
- Value and role of a multi-pronged, tailored thereapeutic approach to CKD
- Strategic and operational considerations for CKD trials in the context of the improved future standard of care

9.30 | 6.30

Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:

- How do you define standard of care?
- What is necessary to see a greater benefit in renal patients?
- What is the challenge and opportunity for additional drug development in CKD?
- What mechanisms and targets hold potential for treatment on top of current treatment?

Jyothis George
Vice President, Clinical, Medical & Regulatory
Novo Nordisk

Richard Nkulikiyinka
VP, Head of Therapeutic Area Cardiology & Nephrology
Bayer Pharmaceuticals

Sibylle Hauske
Senior Medical Director & Global Clinical Development Lead - Empagliflozin in CKD
Boehringer Ingelheim

Uptal Patel
Executive Director of Clinical Research & Head of Nephrology
Gilead

Federica Genovese
Director of Renal & Cardiovascular Research
Nordic Bioscience

10.00 | 7.00

Decoding the Extracellular Matrix in the Kidney - Prognostic, Predictive & Pharmacodynamic Biomarkers for Kidney Fibrosis

10.15 | 7.15

Speed Networking

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the CKD field and establish meaningful business relationships.

10.45 | 7.45 **Morning Break & Networking**

Translational Drug Development Track

Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, **AstraZeneca**

Accessing & Interrogating Data to Inform Drug Target Discovery

11.15 | 8.15 Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification

- Addressing the challenges to develop drugs for complex progressive chronic kidney disease (CKD)
- Defining human kidney transcriptomics-driven approach to better understand molecular mechanisms of progressive CKD and data-driven approach for molecular patient stratification
- Sharing the identification of non-invasive surrogates for molecular mechanisms underlying progressive CKD

Wenjun Ju, Associate Research Scientist of Internal Medicine, **University of Michigan**

11.45 | 8.45 Next-generation Analysis of Kidney Tissue by Super-resolution Microscopy

- Exact and quantitative analysis of the podocyte foot process morphology
- Biomarker detection in histological sections allows a look into the future
- Filtration Slit Density (FSD) - a new and individualized value for kidney disease
- FSD and podocyte number - important for drug research and the rating of the disease progression

Nicole Endlich, Chief Executive Officer, **NIPOKA**; Professor, **University Medicine Greifswald**

Disease Modeling for More Predictive Translation & Mechanistic Discovery

12.00 | 9.00 Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity

- Defining kidney organoids and how they are made
- Describing disease models in kidney organoids and their use in drug development
- Considering ways to integrate organoids into the current pipeline including limitations

Beno Freedman, Assistant Professor – Nephrology, **University of Washington**

12.30 | 9.30 Bioengineering Technologies to Model Renal Systems

- Understanding how 'kidney on a chip' microphysiological systems can be used for disease modeling
- Demonstrating how 'kidney on a chip' microphysiological systems can be used for toxicity testing
- Discussing how 'kidney on a chip' microphysiological systems can be used for physiologically based pharmacokinetic modeling

Jonathan Himmelfarb, Director of the Kidney Research Institute & Professor of Medicine, **University of Washington**

Clinical Drug Development Track

Track Moderator: Kevin Fowler, President, **The Voice of the Patient**

Considerations & Tools to Inform Clinical Decisions & Success

11.15 | 8.15 Biomarkers as Key Drug Development Tools

- Overview of biomarker use throughout drug development for CKD
- Highlighting examples including tubular injury biomarkers
- Discussing global consortia's efforts on glomerular damage biomarkers including examples of use of biomarkers in drug development

Vishal Vaidya, Translational Omics Group Head, **Pfizer**

11.45 | 8.45 15 minute Break

12.00 | 9.00 From Diagnostic to Therapeutic Targets

- Overviewing the development of novel renal biomarkers at BPM
- Showcasing PTM associated with the renal disease progression and potential mechanisms behind these
- Sharing how the first PTM ELISA, DNlite-IVD103 predicts eGFR decline in diabetes

Tzu-Ling (Karen) Tseng, Chief Executive Officer, **Bio Preventive Medicine Corp**

12.30 | 9.30 Renal Function Surrogates for Trial Endpoints & Clinical Decision Support: Are we Reshuffling an Old Deck or Adding New Cards to the Table?

- Discussing practical biomarkers for study endpoints: slopes, ratios, and what regulators want to see
- Evaluating advances in medical imaging: a search for function with quantitative analysis

Joseph Stavas Senior Vice President, Clinical Development, **inRegen**

1.00 | 10.00 **Lunch Break**

Implementing Precision Medicine in Renal Disease
Studying Genetic Drivers & Targetable Mutations in Chronic Kidney Disease

1.45 | 10.45 **Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems**

- Evaluating the practicalities and potential of achieving regulatory approval in orphan indications as a gateway to trials to larger CKD populations
- Critically discussing the benefits and disadvantages to industry and patients
- Evaluating working examples from the current landscape

Jeff Hafkin
Senior Director
Otsuka Pharmaceuticals

Josh Tarnoff
Chief Executive Officer
NephCure Kidney International

Uptal Patel
Executive Director of Clinical Research & Head of Nephrology
Gilead

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics
University of Michigan

2.15 | 11.15 **Pathway Driven Patient Stratification in Glomerular Disease: A Report From the Trenches**

- Transitioning from observation to action: Using a comprehensive multi scalar knowledge network to define pathway activity on a patient level in CKD
- Linking pathway activity with ongoing opportunities for clinical trials in glomerular disease
- Establishing the framework for patient pathway matching in clinical trials and care

2.45 | 11.45 **Panel Discussion: Executing Precision Medicine in Clinical Trials**

- How big an opportunity is precision medicine in the kidney space?
- What are the practical and logistical frameworks to draw parallels between molecular signatures and clinical trials?

Maria Gomez
Professor of Physiology
Head, Diabetic Complications Unit
Director
Lund University Diabetes Centre (LUDC)

Andrew King
Head of Renal Discovery & Translational Medicine
Chinook Therapeutics

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics
University of Michigan

Liron Walsh
Vice President of Translational & Clinical Nephrology
Goldfinch Bio

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

3.15 | 12.15 **Afternoon Break & Poster Session**

Share and listen to poster abstract presentations in small groups to learn and network with peers and connect over mutual points of interest. Rotate around poster presentations to in 5 minute intervals, just like in a real life poster session!

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

4.00| 1.00 **APOL1 – A Genetic Driver of Kidney Disease: From Concept to Clinical Trials**

- Identifying genetic drivers of kidney disease using genomics
- APOL1 variants drives kidney disease in large numbers of patients
- Evaluating APOL1 inhibition in clinical trials in patients with FSGS

Liron Walsh
Vice President of Translational & Clinical Nephrology
Goldfinch Bio

4.30 | 1.30 **Targeting FSGS as an Entry Point in CKD: Expanding From a Smaller Market**

- Making informed decisions for patient selection and controls with genetic studies
- Progress in healthy volunteer study in FSGS
- Understanding potential for wider activity in other renal disease

5.00 | 2.00 **Chair's Closing Remarks**

Conference Day Two
Thursday March 4

Eastern Standard Time | Pacific Standard Time

Endpoints: How Do We Get a Drug to Market?

Aliza Thompson
Clinical Team Leader, Division of Cardiovascular & Renal Products
FDA

9.00 | 6.00 **Drug Development Considerations for Kidney Diseases: A Regulatory Update**

- Discussing both rare and chronic kidney disease
- Addressing "hot topics" related to the design of development programs for kidney diseases, such as real world evidence, precision medicine, and patient-focused drug development

Shira Perl
Global Clinical Program Lead
AstraZeneca

9.30 | 6.30 **Phase 2a Results, Phase 2b Study Design, & Investigations into the Mechanism of Action of Verinurad, a URAT1 Inhibitor, in Development for CKD & Heart Failure**

- Showing the antiproteinuric effects of verinurad to date
- Describing the design rationale for the ongoing phase 2b assessing composite endpoints of UACR and eGFR slope
- Sharing results to date and ongoing activities to elucidate the mechanism by which verinurad and allopurinol improves albuminuria

Andrew King
Head of Renal Discovery &Translational Medicine
Chinook Therapeutics

10.00 | 7.00 **Selective ETA receptor antagonist ATRASENTAN for the Treatment of Primary Glomerular Diseases**

- Discussing evidence of endothelin pathway activation in primary glomerular diseases
- Relevant biomarker strategies for selecting patients at high risk for progressive renal function loss
- Presenting the clinical development plan using surrogate endpoints to support FDA approval

10.30 | 7.30 **Morning Break & Networking**

Forward Thinking Questions to Shape the Next Generation of Drug Development Decisions

Translational Drug Development Track

Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, **AstraZeneca**

Harnessing AI to Maximize Data Interrogation for Drug Discovery & Validation

11.00 | 8.00 **Use of Artificial Intelligence in CKD Drug Discovery & Disease Understanding**

- Creating novel hypothesis from interrogation of large data sets using AI
- Translating these hypotheses into CKD drug discovery and disease understanding

Pernille Hansen, Senior Director & Head of Bioscience, **AstraZeneca**

11.30 | 7.30 **Use of Human Genetics, Biomarkers & AI to Drive Target Discovery & Validation**

- AI approach to target discovery and validation using human genetics and clinical data
- Using high content omics data for targets and biomarkers discovery
- Using proprietary biobank and clinical data for biomarkers identification

Maria Chiara Magnone, Vice President Kidney Diseases & Boston Site Head, **Janssen**

Clinical Drug Development Track

Track Moderator:
Kevin Fowler, President, **The Voice of the Patient**

Engaging with Patients & Considering Costs of CKD as a Significant Public Health & Orphan Indications

11.00 | 8.00 **The 3 "R"s of Orphan Kidney Disease Research: Risk, Resources & Reimbursement**

- Aligning patient and payor interests and objectives
- De-risking outcomes through relevant biomarkers
- Discussing examples of successful precedents and exemplary programs

Frank Czerwiec, Chief Medical Officer, **Goldfinch Bio**

11.30 | 7.30 **FSGS: Finding the Patients**

- Session details to follow

Josh Tarnoff, Chief Executive Officer, **NephCure Kidney International**

12.00 | 9.00 Using twoXAR's AI-platform for the Discovery & Preclinical Validation of Therapeutic Leads with Novel MOAs for CKD

- Discussing the identification of novel hits for CKD using twoXAR's proprietary AI-platform
- Highlighting pre-clinical validation for two compounds with novel MOAS, TXR-1208 and TXR-1210, that show significant efficacy and excellent tolerability

Anjali Pandey, Senior Vice President of Nonclinical R&D & Chemistry, **twoXAR Pharmaceuticals**

12.00 | 9.00 Panel Discussion: Navigating Enrollment of Minority Patients

- Understanding what trial outcomes are important to patients' and their quality of life
- Integrating patient preference into clinical trial design for more meaningful impact to patients' lives
- Planning and executing patient identification and recruitment globally by establishing cohort outreach and communities across the globe

Kevin Fowler, President, **The Voice of the Patient**

Dorothee Oberdhan, Associate Director, Health Outcomes, **Otsuka Pharmaceuticals**

Josh Tarnoff, Chief Executive Officer, **NephCure Kidney International**

12.30 | 9.30 Lunch Break & Speed Networking Session Two

An opportunity for those in later time zones to meet and establish connections with other conference participants, and a second opportunity for others to re-connect or meet anyone missed before!

Beyond the Results: Dissecting Lessons Learned From Clinical Trial Success

1.30 | 10.30 Panel Discussion: Understanding Renal Fibrosis as a Hallmark of CKD & Debating if Targeting TGF is Best to Reverse it

- Putting renal fibrosis under the spotlight as the 50-million dollar drug target
- Sharing experiences targeting TGF and promising new mechanisms/ targets
- Debating a paradigm shift in anti-fibrotic drug development

Matt Breyer
Distinguished Scientist
Janssen

Ravi Kumar
Senior Vice President & Chief Scientific Officer
Acceleron Pharma

Hitesh Soni
Renal Fibrosis Gene Therapy Lead
Renascent Biosciences

Scott MacDonnell,
Associate Director, Cardiovascular & Fibrosis Research
Regeneron Pharmaceuticals

Yshai Yavin
Director, Cardiovascular & Metabolism Development
Janssen

2.00 | 11.00 Rationale & Results of Subgroup Analyses of the CREDENCE Study

- Reviewing rationale for design of the study
- Sharing results of subgroup analyses

Robert Edwards
Clinical Project Scientist
Janssen

2.30 | 11.30 A Blueprint for Success: Janssen's CREDENCE Clinical Trial

- Patient recruitment: a global multidisciplinary effort required perseverance
- Patient retention: a top priority from day 1 left no stone unturned
- Adjudication: a concerted cross-functional effort required diligence and determination

3.00 | 12.00 Afternoon Break & Networking

Seemi Khan
Senior Vice President, Chief Medical Officer
Reata Pharmaceuticals

3.30 | 12.30 Talk Details to be Revealed

Radko Komers
Senior Medical Director, Nephrology
Travere Therapeutics

4.00 | 1.00 Clinical Development of Sparsentan: A Novel, Dual-acting Endothelin Type A & Angiotensin II AT1 Receptor Antagonist for the Treatment of FSGS & IgAN

- Summarizing current status of sparsentan clinical development in FSGS and IgA nephropathy
- Sharing supporting preclinical evidence in a spectrum of models of progressive kidney diseases

Borut Cizman
Senior Director & Lead Nephrologist, ASCEND Program, Specialty Pharma, R&D
GSK

4.30 | 1.30 Challenges of Clinical Research During the COVID-19 Pandemic

- Describing the challenges of performing global clinical research in CKD and dialysis populations at the time of COVID-19 pandemic
- Presenting coordinated actions from sponsor, CRO and clinical research sites
- Helping pharma organizations and research investigators better understand how to modify performing clinical research and monitoring during the pandemic situations
- Assisting design of research studies in the future incorporating mitigation strategies for pandemic events

5.00 | 2.00 Chair's Closing Remarks & End of Summit

CKD3: The Digital Event Experience

Adapting to the new world, the **digital 3rd CKD3 Summit** will provide industry's best opportunity for knowledge exchange and networking to ensure you **don't miss out on timely scientific insights, data and strategic discussion** on how to deliver more innovative, targeted and clinically successful therapeutics for chronic kidney disease.

In March, join your peers digitally for the first time and immerse yourself in the most comprehensive CKD drug development conference to understand additional drug development opportunity beyond the standard of care.

Built specifically to enable personal online interactions and streamlined, thought leading content from target identification through to navigating enrollment of minority patients; this focused forum will empower biopharma to bring even further life changing drugs to this huge patient population.

Accessing the platform is simple. You will be provided with a unique link in the run up to the event that will take you directly to the online event space. Simply follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:

Delegate Profile
Set up personalized profiles so you and others can easily identify names, job titles & companies of other attendees.

Stage Area
The "stage" areas is where speakers will deliver their presentations and take live Q&A.

Sessions Area
The "sessions" area is where the poster session will be delivered. Present your poster in front of a group of peers and discuss your research directly with interested parties.

Demo Area
Visit the "demo area" to see virtual exhibition booths from our specialist partners and understand how their solutions can support your work.

Chat Rooms
Connect with other delegates and speakers privately or in groups with chatroom conversations. Just scroll through the delegate list and invite someone for a chat!

Speed Networking
These sessions connect you one-to-one in 4 minute intervals with other attendees at the start and close of the conference, so you begin and leave having met everyone you need to.

What You Can Expect from a Digital Event:

Detailed Presentations Followed by Live Q&A
Enter questions into the live chat during presentations for the speakers to answer during their allocated Q&A, just as they would at a physical conference.

Audience Discussions
Present to, or join in, small groups to share, evaluate and discuss attendees research, challenges and points of interest during our intimate poster session.

Organized & Candid Networking Sessions
Facilitated and informal networking breaks will give you multiple opportunities to meet and connect with everyone else in attendance so you are guaranteed to leave having made connections.

Content Available Post-Event
Where possible, presentations and recordings will be available after the event to attendees so you can follow up with any slides you need once the day is done.

If you have any other questions about the platform, please get in touch via info@hansonwade.com

2021 Partners

Program Partner

Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company. BPM has been focus on translating validated and IP-protected biomarkers into diagnostic solutions for unmet clinical needs, especially in Diabetic Kidney Disease (DKD) and non- proteinuric renal disease. Our first IVD product, DNlite-IVD103, has been CE IVD marked in January 2020. DNlite-IVD103 is an ELISA test detecting a post translational modification of a DKD biomarker, identified by large urinary proteomic studies. DNlite-IVD103 is a non-invasive urinary test for predicting/monitoring the progression of DKD.

www.bpmbiotech.com

Spotlight Partner

NIPOKA was found as a spin-off from the University Medicine and University Greifswald (Germany). The team has over 20 years of expertise in podocyte research. NIPOKA offers a revolutionary procedure, that enables to determine the exact foot process morphology in biopsies and kidney sections of mice and rats. We can reliably identify foot process effacement without bias in a short time. The procedure is based on super-resolution microscopy and does not require electron microscopy.

www.nipoka.com

Spotlight Partner

Nordic Bioscience has more than 25 years' experience in biomarker development and integrating these biomarkers into clinical trials with extensive scientific expertise in the fields of fibrosis, rheumatology, immunology and oncology. Using our unique biomarker technology, we identify predictive and prognostic biomarkers which are used to enrich clinical trials and may reduce trial length and size required to determine therapeutic efficacy. With over 500 publications in leading journals, we pride ourselves with our highly scientific approach and mindset. Welcome to the Biomarker Powerhouse!

Www.nordicbioscience.com

Exhibition Partner

DiscoveryBioMed, Inc. (DBM) is a boutique R&D and CRO biotechnology company that leverages human cell platform technologies for drug discovery and validation in renal, respiratory, and metabolic therapeutic areas. DBM currently offers highly advanced 3D human cell based in vitro cyst forming models of Polycystic Kidney Disease (PKD) with development underway for a similar system for Chronic Kidney Disease (CKD).

www.DiscoveryBioMed.com

Interested in Becoming a Partner?

Matt Ashman
Partnerships Manager
Tel: (+1) 617 455 4188
Email: sponsor@hansonwade.com

2021 Partners

Exhibition Partner

Evotec is a Drug Discovery Alliance and Development Partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic.

www.evotec.com

Twitter:@Evotec.

Exhibition Partner

Frenova is the world's only drug and medical device contract clinical development services provider dedicated exclusively to renal research and its adjacent conditions. As a Fresenius Medical Care North America company, Frenova manages clinical research assets and resources including over 450 principal investigators at more than 260 sites representing 160 medical practices. Frenova's F1RST Up® network of select investigative sites provides sponsors with accelerated study startup, while Frenova's SMO manages clinical research staff and streamlines trial operations to help investigators enroll more patients and perform more studies.

www.FrenovaRenalResearch.com

Exhibition Partner

Gubra is a privately held biotech located in Denmark delivering scientific counselling, contract research services, and projects for co-development in five main areas: Obesity, diabetes, NASH, kidney, and heart diseases. Gubra experts cover pre-clinical disciplines such as in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS, bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers.

www.gubra.dk/cro-services/cro-ckd

Partner with the 3rd CKD3 Summit

Virtual Exhibition Hall

Run your product demo for your prospect customers at your virtual exhibition booth and answer their questions in real time.

REQUEST A DEMO

Raise Brand Awareness & Position Yourself as an Industry Thought Leader

Demonstrate your expertise by showcasing your technology solutions alongside heads from leading pharma, biotechs and academia.

Meet & Network with Industry Pioneers

With advanced access to the attendee list, we will help you organize pre-scheduled 121 meetings with individuals key to your business development objectives so you can start the conference ready to maximize every minute online.

Interested in Becoming a Partner?

Matt Ashman
Partnerships Manager
Tel: (+1) 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

www.ckd3-summit.com/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

What will you takeaway from CKD3?

1. Unique KOL insights to better align your own research with the pace and direction of your peers
2. Understanding of next generation modalities and machine learning to optimize novel target discovery from big data sets and the development of your own pipeline
3. Valuable new and strengthened connections with key thought leaders to advise and steer your pipeline's acceleration

Team Discounts*

- **Teams of 2-3 delegates: 10% discount**
- **Teams of 4+ delegates: 20% discount**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time
Contact: register@hansonwade.com

SECURE YOUR PLACE

Standard Pricing	Register & pay by Friday January 29, 2021	Final Online Pricing
Full Attendance (Conference + Workshop)	$2,629 **(save $191)**	$2,720 **(save $100)**
Conference Only	$2,099 **(save $70)**	$2,169
Workshop Only	$630	$651
Small Biotech & Academic*	Register & pay by Friday January 29, 2021	Final Online Pricing
Full Attendance (Conference + Workshop)	$1,628 **(save $191)**	$1,719 **(save $100)**
Conference Only	$1,329 **(save $70)**	$1,399
Workshop Only	$399	$420

*reduced rate is available for academics and startup biotechs (established for 5 years or less and evidence of internal pipeline development on website)
If you are a UK or EU-based company, you may be subject to VAT in addition to the price advertised

> "Very efficient and convenient way for the audience to get updated on the challenges various stake holders are facing while dealing with this devastating disease"
>
> **Hanson Wade Digital Delegate**